Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces it has entered into a partnership agreement with SymbioPharm, a German company pioneering in microbiome research and knowledge-based probiotics. SymbioPharm has secured its position as a leading innovator and provider of probiotics, medicinal products and dietary supplements in Germany, Austria and Switzerland where it is considered a top tier consumer brand. SymbioPharm's distribution network spans direct-to-consumer channels as well as a comprehensive online and offline pharmacy presence.
The agreement allows SymbioPharm to utilise ProBiotix's CholBiome® CH formulation to target and reduce cholesterol in their branded consumer products. SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions. The agreement covers sales in Germany, Austria and Switzerland, focusing on maximising market penetration through strategic pharmacy partnerships.
The unique and innovative formulation developed by ProBiotix comes with a European Food Safety Authority (EFSA) health claim, specific for cholesterol.
Steen Andersen, CEO of ProBiotix Health plc commented: "We are delighted that Symbiopharm, a recognised leader in the probiotic space, has engaged with ProBiotix Health. This collaboration is strategically aligned with our goal of extending the reach of our unique finished product formulations within the DACH region (Germany, Austria and Switzerland). This is an important step for us to further expand our business in the consumer health segment, and allow us to reach a broader audience, enhancing market presence and influence."
Tobias Brodtkorb, CEO of SymbioPharm added: "We are very pleased to have entered into this agreement with ProBiotix Health. We are a collaborative business and are passionate about natural treatments using live bacteria. Our focus is not only on effective therapies, but also on the associated diagnostics and scientific research on the microbiome, and we find our model fits in naturally with ProBiotix and their mission. We are delighted to be working closely with them and hope for a strong relationship going forward."
SymbioPharm's apparent reputation and access to market, incl pharmacies should help sales.
Isn't this the same agreement announced in the Sep Results RNS?
" Closing of long-term commercial agreement with third largest supplement brand in Germany. The agreement is aiming at launching CholBiome® CH - our newest product line extension - in Germany during Q4 this year. The launch will eventually be broadened to include Austria and Switzerland."
So confirmation the agreement has been signed off, albeit a little behind schedule.
Also, this shows how agreements on partnerships and commercialisation are like wading through treacle.
Agree Dire, guess we have to wait for the partner to set up its manufacturing capability before an eventual launch then
The rns states...
SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions...
Sounds like the formulation is already on sale?
Https://www.symbiopharm.de/produkte/symbiolife-praezisionsprobiotika/symbiolife-cholesterin-control
Thanks BK, translation of the page below
"Dual-Level Support: SymbioLife® Cholesterol Control* provides support to our body on two levels, naturally normalizing cholesterol levels.
It contains the bacterium Lactobacillus plantarum LPLDL®, harnessing the significant impact of natural bacteria on our health. Intestinal bacteria, particularly of the Lactobacillus genus, can regulate our cholesterol levels by binding to cholesterol or incorporating it into their own cell membranes.
The specific intestinal bacterium Lactobacillus plantarum LPLDL® also increases our excretion of bile acids. As a result, our body produces more bile acids, which are essential for fat digestion, and in turn, removes cholesterol from the blood.
In addition to this, SymbioLife® Cholesterol Control contains phytosterols*, secondary plant compounds that possess a structure similar to cholesterol. When we consume phytosterols, our intestinal wall transports them into our body instead of cholesterol.
The remaining cholesterol in the intestine is then excreted with the stool, leading to a decrease in cholesterol levels"
Thanks for putting me straight on this. It is the same company as referred to in half year report.